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Introduction
Platelets are small, anucleate cells critical to the hemostatic
process.1Upon vessel injury, platelets are activated via interac-
tion of cell surface receptors with collagen and subsequent
activation via soluble agonists such as adenosine diphosphate
(ADP), thromboxane A2 (TXA2), and thrombin, leading to a
cascade of intracellular events including calciummobilization,
granule secretion, and integrin activation.2 This leads to the
formation of platelet aggregates, development of thrombi, and
Keywords
► platelets
► quercetin
► aspirin
► ﬂavonoids
► thrombosis
Abstract Quercetin, a dietary ﬂavonoid, has been reported to possess antiplatelet activity. However,
its extensive metabolism following ingestion has resulted in difﬁculty elucidating precise
mechanisms of action. In this study, we aimed to characterize the antiplatelet mechanisms
of two methylated metabolites of quercetin—isorhamnetin and tamarixetin—and explore
potential interactions with aspirin. Isorhamnetin and tamarixetin inhibited human platelet
aggregation, and suppressed activatory processes including granule secretion, integrin
αIIbβ3 function, calciummobilization, and spleen tyrosine kinase (Syk)/linker for activation
of T cells (LAT) phosphorylation downstream of glycoprotein VI with similar potency to
quercetin. All three ﬂavonoids attenuated thrombus formation in an in vitro microﬂuidic
model, and isoquercetin, a 3-O-glucoside of quercetin, inhibited thrombosis in a murine
laser injury model. Isorhamnetin, tamarixetin, and quercetin enhanced the antiplatelet
effects of aspirin more-than-additively in a plate-based aggregometry assay, reducing
aspirin IC50 values by an order ofmagnitude, with this synergymaintained in a whole blood
test of platelet function. Our data providemechanistic evidence for the antiplatelet activity
of two quercetin metabolites, isorhamnetin and tamarixetin, and suggest a potential
antithrombotic role for theseﬂavonoids. In combinationwith their interactionswithaspirin,
this may represent a novel avenue of investigation for the development of new antith-
rombotic strategies and management of current therapies.
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the cessation of bleeding. The activation of this cascade under
pathophysiological conditions can, however, result in the
occlusion of vessels through thrombus formation, or thrombo-
sis, leading to events such as stroke or myocardial infarction.3
The pharmacological targeting of platelet activation pathways
with antiplatelet medications has proven very successful;
medications such as aspirin, the most widely used agent
worldwide, are, however, associated with a lack of effect in
some patients, and are associated with adverse events such as
bleeding, raising a priority for the development of more
efﬁcacious and safer alternative therapeutic approaches.4,5
The link between diet and cardiovascular disease (CVD) is
well established, with many cohort studies demonstrating the
beneﬁcial effects of fruit and vegetable intake, and speciﬁcally
ﬂavonoid intake, on cardiovascular health.6,7 Quercetin is a
commonly consumed ﬂavonoid found in foods such as apples,
onions, and red wine, and has demonstrated beneﬁcial prop-
erties innumerous studies reporting anticancer, antimicrobial,
and antiviral effects.8,9 In addition to this, quercetin intake has
been implicated in reducedCVDrisk inboth interventional and
observational studies, with intake linked to a reduction in
plasma low-density lipoprotein, reduced systolic and diastolic
blood pressure, and reduced riskof ischemic heart disease.10,11
Quercetin is also reported to possess antiplatelet effects, with
an inhibition of platelet aggregation upon in vitro addition as
well as ex vivo post-supplementation.12,13 These antiplatelet
effects have not, however, been fully characterized.
Upon consumption, quercetin is metabolized extensively in
the small intestine and liver, yielding conjugated metabolites;
the antiplatelet effects of these invivo “effectors”have received
considerably less attention.14 Further to this, the potential for
interactions between quercetin, its metabolites, and currently
used antiplatelet medications such as aspirin is an important
avenueof investigation; interactionsbetween thesesubstances
must be explored in order to understand the nature of anti-
platelet efﬁcacy upon their simultaneous presence in plasma.
In this study, we investigate the antiplatelet effects of
isorhamnetin and tamarixetin, two methylated metabolites
of quercetin, which were found to inhibit platelet function
through effects on granule secretion, integrin activation,
calcium mobilization, and phosphorylation of key signaling
proteins downstream of glycoprotein VI (GPVI), resulting in
antithrombotic effects in vitro. In addition, antithrombotic
effects of isoquercetin were displayed in a murine model of
thrombosis, and we provide compelling evidence that quer-
cetin and its metabolites synergize with aspirin in the
inhibition of platelet function.
Materials and Methods
Materials
Tamarixetin, isorhamnetin, and quercetin-3-glucuronidewere
from Extrasynthese (Lyon, France). Isoquercetin was from
Quercegen Pharmaceuticals LLC (Massachusetts, United
States). Fibrillar type I collagenwas fromTakeda (Linz, Austria),
and cross-linked collagen-related peptide (CRP-XL) was pro-
vided by Professor Richard Farndale (University of Cambridge,
United Kingdom). Phycoerythrin (PE)/Cy5 antihuman CD62P
antibody was from BD Biosciences (New Jersey, United States),
and ﬂuorescein isothiocyanate (FITC) antihuman ﬁbrinogen
antibodywas fromDako (Glostrup, Denmark). Anti-LAT (linker
for activation of T cells) phosphotyrosine 200 and anti-Syk
(spleen tyrosine kinase) phosphotyrosine 525þ 526 antibod-
ies were from Abcam (Cambridge, United Kingdom). Alexa-
Fluor 488 donkey antigoat, Alexa-Fluor 647 donkey antirabbit
conjugated antibody, and Fura-2 AMwere from Life Technolo-
gies (Paisley, United Kingdom). Anti-β3 integrin (N-20) goat
polyclonal antibody was from Santa-Cruz Biotechnology
(Heidelberg, Germany). DyLight 649 conjugated anti-GPIbα
antibody was from EMFRET analytics (Würzburg, Germany).
CHRONO-LUME ATP detection kit was from Chronolog
(Pennsylvania, United States) and Alexa-Fluor 488 conjugated
phalloidin was from Thermo-Fisher Scientiﬁc (Massachusetts,
United States). Precision Plus Protein dual color standard,
10X Tris/Glycine/SDS buffer, Immun-Blot PVDF membrane,
and 4–20% Mini-PROTEAN TGX (tris-glycine eXtended)
precast protein gels were from Bio-Rad (Hertfordshire,
UnitedKingdom). 96-wellﬂat bottomplateswere fromGreiner
Bio-One (Stonehouse, United Kingdom). Vena8 Fluoroþ bio-
chips were from Cellix Ltd (Dublin, Ireland). Platelet function
analyzer (PFA)-100 cartridges were from Sysmex (Milton
Keynes, United Kingdom). All other reagents were from Sigma
Aldrich (Gillingham, United Kingdom).
Methods
Light transmission measured via aggregometry, P-selectin
exposureandﬁbrinogenbindingmeasuredviaﬂowcytometry,
dense granule secretion measured via lumi-aggregometry,
adhesion and spreading on ﬁbrinogen, clot retraction, and
calcium mobilization were performed using standard techni-
ques as described previously.15–19 Immunoblotting was per-
formed using standard protocols as described previously, with
proteins of interest detected using speciﬁc antibodies
raised against them and ﬂuorophore-conjugated secondary
antibodies.16ATyphoonFLA9500scanner (GEHealthcare)was
used to visualize proteins, and protein levels were normalized
to loading controls.
Platelet Preparation
Washed platelet preparation was performed via differential
centrifugation as described previously.16 Platelets were
resuspended to the appropriate density in modiﬁed
Tyrodes-HEPES buffer (134mM NaCl, 2.9mM KCl, 12mM
NaHCO3, 0.34mM Na2HPO4, 1mM MgCl2, 20mM N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid, 5mM
glucose, pH 7.3) and rested at 30 °C for 30minutes before use.
Plate-Based Aggregometry
Plate-based aggregometry was performed as previously
described by Chan et al.20 Washed platelets (2 108 cells/
mL) or platelet-rich plasma (PRP) were loaded into 96-well
plates and incubated with vehicle control or ﬂavonoids
(5 minutes in washed platelets, 30minutes in PRP), aspirin
(30minutes), or both, prior to agonist addition, after which
plates were shaken at 1,200 rpm for 5minutes at 37 °C using
a BioShake iQ (Quantifoil Instruments, Jena, Germany).
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Transmission of light (405 nm) was measured using a
NOVOstar plate reader (BMG Labtech, Aylesbury, United
Kingdom ), and values converted to percentage aggregation
using unstimulated and agonist-stimulated samples to rep-
resent 0 and 100%, respectively.
In Vitro Thrombus Formation
Citrated human whole blood was incubated with 5 μM DiOC6
for 1 hour at 30 °C, and Vena8 BioChip microﬂuidic channels
were coated for 1 hour with type I collagen at room tempera-
ture; excess collagen was washed through the channels with
modiﬁed Tyrodes-HEPES buffer. Whole blood was incubated
with ﬂavonoids or vehicle control for 10minutes at 30 °C prior
toperfusion throughmicroﬂuidicchannels at a shear rate of20
dyn/cm2. Using a Nikon A1-R confocal microscope, ﬂuores-
cence was excited at 488 nm, and emission detected at 500 to
520 nm; the channel was observed under a 20 objective and
images captured every second for 600 seconds. Mean ﬂuores-
cence intensitywassubsequentlycalculatedwithNISElements
software (Nikon, Tokyo, Japan).
Thrombus Formation In Vivo
C57/BL6 mice were dosed with isoquercetin twice per day by
oralgavage, once in themorningandonce in theafternoon. This
was performed for 48 hours prior to commencement of the
experiment, with one ﬁnal dose in the morning of the experi-
ment. Mice were anaesthetized by intraperitoneal ketamine
(125mg/kg), xylazine (12.5mg/kg), and atropine (0.25mg/kg)
injection, and maintained with pentobarbital (5mg/kg) as
required, through a carotid artery cannula. The cremaster
muscleof the testiclewasafﬁxedoveraglass slide, andplatelets
were labeled with DyLight 649 anti-GPIbα antibody (0.2 μg/g
mouseweight).Arteriolewallswere injuredusingaMicropoint
ablation laser unit (Andor Technology PLC, Belfast, Northern
Ireland),with thrombus formation observed using an Olympus
BX61W1 microscope (Olympus Corporation, Tokyo, Japan).
Images were captured prior to and after injury using a Hama-
matsu digital camera (C9300 charge-coupled device camera;
Hamamatsu Photonics UK Ltd, Hertfordshire, UnitedKingdom)
in 640 480 format. Images were analyzed using Slidebook 6
software (Intelligent Imaging Innovations, Colorado, United
States). Experiments in mice were performed under a UK
Home Ofﬁce license after approval from the University of
Reading Local Ethical Review Panel.
Platelet Function Analyzer 100
Citrated human whole blood was incubated with ﬂavonoids,
aspirin, or vehicle control for 30minutes at 30 °C, after which
800 μLwaspipetted intothereservoirofPFA-100testcartridges.
Cartridges were loaded into the PFA-100 analyzer carousel and
samples were run in an automated process, drawing blood
throughanaperture ina collagen/ADPorcollagen/epinephrine-
coated membrane at a shear rate of 5,000 to 6,000 s1, and
outputting a closure time (CT) upon occlusion.
Statistical Analysis
Statistical analyses were performed using Prism Version 7
(Graphpad, California, United States). Aspirin plus ﬂavonoid
aggregometry data were analyzed by two-way analysis of
variance (ANOVA) with posthoc Dunnett’s multiple compari-
sons test. In vitro thrombus formation and protein phosphory-
lation data were analyzed by two-way ANOVA with posthoc
Bonferroni multiple comparison test. In vivo thrombus forma-
tion data were analyzed by unpaired t-tests, and synergistic
(more-than-additive) effects were established using paired
t-tests. All other data were analyzed by one-way ANOVA with
posthocDunnett’smultiple comparison test.Dataarepresented
asmean standard error ofmean (SEM), with p 0.05 consid-
ered statistically signiﬁcant.
Results
Tamarixetin and Isorhamnetin Inhibit Platelet
Aggregation Evoked by Collagen
Collagen is exposed on the subendothelium upon vessel
injury, and is a key activatory substance in the hemostatic
response.21We therefore investigated whether keymetabol-
ic changes to quercetin (i.e., methylation) affected the ability
to inhibit collagen-stimulated washed platelet aggregation.
Reported physiological plasma concentrations vary widely
according to supplementation/dietarymethod, dose, and the
form of quercetin administered; a range between 0 and 10
μM was used here (and throughout) to represent a feasible
physiological concentration range (with the upper level of
10 μM representing a high yet achievable plasma concentra-
tion of total quercetin).12,22,23
Isorhamnetin, the 3′-methylated metabolite of quercetin,
concentration-dependently inhibited collagen-stimulated
platelet aggregation with an IC50 (half-maximal inhibitory
concentration) value of 4.76 0.99 μM (►Fig. 1A, B). In
contrast to this, tamarixetin, the 4′-methylated metabolite
of quercetin, displayed reduced potency, inhibiting platelet
aggregation fully at concentrations above 20 μM,with an IC50
value of 7.21 0.33 μM (►Fig. 1C, D). Quercetin inhibited
aggregation at concentrations >5 μM, with an IC50 of 5.72
0.51 μM (►Fig. 1E, F). The structures of the ﬂavonoids
investigated are shown in ►Supplementary Fig. S1. These
results indicate that methylation at the 3′-position (isorham-
netin) confers a moderately higher inhibitory potency com-
pared to methylation at the 4′-position (tamarixetin) or
possession of a B ring catechol moiety (quercetin). This
was conﬁrmed upon stimulation with multiple collagen
concentrations, with isorhamnetin displaying the most po-
tent inhibitory proﬁle (►Supplementary Fig. S2). In addition
to this, isorhamnetin, tamarixetin, and quercetin inhibited
aggregation evoked by ADP, U46619 (a stable TXA2 analog),
and thrombin, providing evidence for G-protein coupled
receptor (GPCR)-mediated pathway inhibition by the meth-
ylated metabolites of quercetin (►Supplementary Fig. S3).
Platelet Granule Secretion is Inhibited by the
Methylated Metabolites of Quercetin
The secretion of platelet granules is a key process driving the
positive feedback cycle of activation; dense granules are rich
in small molecules such as adenosine triphosphate (ATP),
ADP, and serotonin, and α-granules contain proteins such as
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ﬁbronectin, P-selectin, and vonWillebrand factor.24 In order
to elucidate whether the antiaggregatory effects of tamarix-
etin and isorhamnetin were due to an upstream effect on
dense granule secretion, collagen-stimulated (5 μg/mL)
secretion of ATP from washed platelets was investigated.
Isorhamnetin, tamarixetin, and quercetin inhibited dense
granule secretion; a concentration-dependent reduction in
ATP secretion was observed with isorhamnetin between 2.5
Fig. 1 Isorhamnetin and tamarixetin, themethylatedmetabolites of quercetin, inhibit collagen-stimulated platelet aggregation.Washed human platelets
(2 108 cells/mL) were incubated with isorhamnetin (A, B), tamarixetin (C. D), quercetin (E, F), or vehicle (DMSO, 0.2% v/v) for 5minutes (with 10 seconds
stirring tomix) prior to addition of collagen (5 µg/mL). Aggregationwasmeasured for 5minutes at 37 °C under constant stirring (1,200 rpm) conditions in a
Chrono-Log optical platelet aggregometer. (A, C, E) Representative traces from aggregation assays. (B, D, F) Four-parameter nonlinear regression curves
used to estimate the IC50 of isorhamnetin, tamarixetin, and quercetin. N¼ 3, data represent mean SEM. I, isorhamnetin; T, tamarixetin; Q, quercetin.
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and 10 μM, with 76 4.4% inhibition at the highest concen-
tration tested (10 μM; ►Fig. 2A, B). Secretion was reduced
signiﬁcantly by tamarixetin at concentrations between 5 and
10 μM (►Fig. 2E, F). Quercetin effected dense granule secre-
tion similarly to tamarixetin, with a maximal inhibition of
70 3.9% at 10 μM (►Fig. 2I, J).
The ability of tamarixetin and isorhamnetin to attenuate the
exposure of P-selectin upon stimulation with collagen-related
peptide (1 μg/mL CRP-XL, cross-linked: a GPVI-selective ligand
that is compatible with ﬂow cytometry analysis) was also
investigated, as a marker of α-granule secretion. Isorhamnetin
inhibited signiﬁcantly this process at all concentrations tested,
with a 39 4.9% reduction in P-selectin exposure upon treat-
mentwitha lowﬂavonoidconcentrationof0.5 μM(IC50:2.57
1.91 μM;►Fig. 2C, D). Tamarixetin inhibited comparably, with
a signiﬁcant effect at 1 μM plus and an IC50 of 2.71 0.27 μM
(►Fig. 2G, H). Quercetin also attenuated P-selectin exposure as
low as 0.5 μM (14 2.7% inhibition), a readily achievable phys-
iological concentration, with an IC50 of 2.51 0.23 μM
(►Fig. 2K, L). Overall, these data suggest that one of the key
mechanisms through which isorhamnetin and tamarixetin
inhibit aggregation is through an early effect on granule
secretion.
Integrin αIIbβ3 Signaling Is Modulated by the
Quercetin Metabolites Tamarixetin and Isorhamnetin
Upon activation, signals from within the platelet function to
upregulate the afﬁnity of integrin αIIbβ3 into an “open” state
(via “inside-out signaling”), to which ﬁbrinogen binds, ulti-
mately leading to aggregation.25 As it is known that quercetin
functions as a broad spectrum inhibitor of protein kinases, it
was hypothesized that this integrin afﬁnity regulationmay be
modulated by the ﬂavonoids. This was measured by investi-
gating CRP-XL (1 μg/mL) stimulated ﬁbrinogen binding to
“open” integrin αIIbβ3. All three ﬂavonoids tested inhibited
signiﬁcantly the binding of ﬁbrinogen; upon treatment with
isorhamnetin, a signiﬁcantly increased level of inhibition at
lower ﬂavonoid concentrations (1 μM) compared to quercetin
and tamarixetin was observed (p< 0.05), with 34 3.5% inhi-
bition at 1 μM (►Fig. 3A). Isorhamnetin reduced ﬁbrinogen
Fig. 2 Isorhamnetin, tamarixetin, and quercetin inhibit platelet granule secretion. Washed platelets (4  108 cells/mL) were treated with
ﬂavonoid or vehicle control (DMSO, 0.25% v/v) for 5 minutes, with 50 μL Chronolume luminescent substrate added in 2 minutes prior to
stimulation. Collagen (5 μg/mL) was added to stimulate platelets and ATP secretion was monitored for 180 seconds under stirring conditions
(1,200 rpm) at 37 °C. (A, E, I) Representative traces showing increase in luminescence upon ATP secretion and inhibition by ﬂavonoids. (B, F, J)
ATP secretion as a percentage of the amount secreted in the absence of isorhamnetin, tamarixetin, or quercetin (vehicle). Washed platelets (2 
108 cells/mL) were incubated with isorhamnetin (C, D), tamarixetin (G, H), quercetin (K, L), or vehicle control (DMSO, 0.25% v/v) for 5 minutes,
after which PE/Cy5 antihuman CD62P antibody was added to the sample prior to stimulation. Samples were then stimulated with CRP-XL (1 μg/
mL) for 20 minutes, after which they were ﬁxed in 0.2% paraformaldehyde. P-selectin exposure on the cell surface was then measured by ﬂow
cytometry and data normalized to the level of P-selectin exposure in the absence of ﬂavonoid (vehicle) (D, H, L). Four-parameter nonlinear
regression curves were utilized to estimate the IC50 of isorhamnetin (C), tamarixetin (G), and quercetin (K). N¼ 3, data represent mean  SEM.
p< 0.05, p< 0.005, p< 0.0001 compared to vehicle control, analyzed by one-way ANOVA with posthoc Dunnett’s test. I, isorhamnetin; T,
tamarixetin; Q, quercetin.
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binding between 1 and 10 μM, as did tamarixetin, with IC50
values of 6.27 2.81 and 5.29 1.58 μM, respectively
(►Fig. 3A, B). Quercetin attenuated ﬁbrinogen binding at all
concentrations tested, with>25% inhibition at 0.5 μM. Indeed,
over 95% inhibitionwas achievedupon treatmentwith 7.5 μM,
with an IC50 value of 3.13 0.46 μM (►Fig. 3C).
Upon ligand binding to integrin αIIbβ3, receptor clustering
causes “outside-in” signaling events that result in platelet
spreading, platelet thrombus contraction, and ultimately
downstream clot retraction.26 In order to determine whether
outside-in signalingmay be affected by themethylatedmetab-
olites, platelet spreading on ﬁbrinogen was investigated. All
Fig. 3 Integrin αIIbβ3 afﬁnity and function is altered by quercetin’s methylated metabolites. Washed platelets (2 108 cells/mL) were incubated with
isorhamnetin (A), tamarixetin (B), quercetin (C), or vehicle control (DMSO, 0.25% v/v), stimulatedwithCRP-XL (1 µg/mL), and ﬁbrinogenbindingmeasured by
ﬂow cytometry. Data normalized to the level of ﬁbrinogen binding in the absence of ﬂavonoid (vehicle). Washed platelets (2 108 cells/mL) were incubated
with isorhamnetin (E), tamarixetin (F), quercetin (G), or vehicle control (DMSO 0.33% v/v) for 5minutes, then allowed to spread on ﬁbrinogen (100 µg/mL)
coated coverslips for 45minutes at 37 °C. Cells were stained with Alexa ﬂuor 488 phalloidin and visualized using a Nikon A1-R confocal microscope. Data
representpercentageofplatelets in each stageof spreading (E–G),mean SEM,with representative images in (D). PRPwas incubatedwith isorhamnetin (H),
tamarixetin (I), quercetin (J),or vehiclecontrol (DMSO,0.2%v/v) for60minutes at30 °C, afterwhich thrombin (1U/mL)wasadded to stimulate clot formation.
The assay was terminated at 120minutes when vehicle-treated clots had retracted fully, with representative images shown as well as clot weight at 120
minutes. N¼ 4, data representmean SEM. p< 0.05, p< 0.005, p< 0.001, p< 0.0001 compared to vehicle control, analyzed by one-way ANOVA
with posthoc Dunnett’s test. I, Isorhamnetin; PRP, platelet-rich plasma; Q, quercetin; T, tamarixetin.
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ﬂavonoids tested inhibited signiﬁcantly platelet adhesion on
ﬁbrinogen at 1, 2.5, and 5 μM (representative images shown
in►Fig. 3D). The spreading of platelets on ﬁbrinogenwas also
inhibitedupon treatmentwithﬂavonoid concentrationsas low
as 1 μM, with fewer platelets able to fully form lamellipodia,
instead progressing only to the adhered orﬁlopodia-extending
stages (►Fig. 3E–G). Consistent with other functional data in
washed platelets, isorhamnetin proved signiﬁcantly more
potent (p< 0.05) than quercetin and tamarixetin at lower
concentrations (1 μM).
Clot retractionwas also investigated as ameasure ofoutside-
in signaling, utilizing PRP and a thrombin-stimulated clot.
Retraction was inhibited by isorhamnetin and tamarixetin
between 2.5 and 10 μM, and by quercetin between 5 and 10
μM. Indeed, ►Fig. 3 (H–J) shows that, upon 10 μM treatment,
retraction of clots was reduced substantially after 2 hours
(when vehicle-treated clots had fully retracted). Tamarixetin
had the largest effect, with a 6.5 larger clot weight at 2 hours
compared to vehicle control; this suggests that, in the presence
of plasma proteins, a 4′-methyl group confers increased inhibi-
tory potency. This is supported by the observation that tamar-
ixetin inhibits signiﬁcantly platelet aggregation in PRP at
concentrations of 10 μM and higher, with quercetin and
isorhamnetin inhibiting signiﬁcantly at 25 μM (the higher
concentrations required here may be explained by stirring
conditions and use of collagen [5 μg/mL] as agonist;
►Supplementary Fig. S4). These data display inhibitory effects
of quercetin and its methylated metabolites at physiologically
achievable concentrations in the presence of plasma proteins,
and suggest a role for these ﬂavonoids in integrin αIIbβ3
outside-in signaling inhibition.
Isorhamnetin Potently Inhibits CRP-XL Stimulated
Cytosolic Calcium Elevation
The mobilization of calcium from intracellular platelet stores
and the entry of calcium into the cell are crucial for platelet
activation, driving granule secretion and integrin αIIbβ3 acti-
vation.27As thesedownstreamprocesseswere inhibited, itwas
investigated whether an upstream effect on calciummobiliza-
tion was associated with diminished platelet responses. Cyto-
solic calcium elevation stimulated by CRP-XL (1 μg/mL) was
inhibited signiﬁcantly by isorhamnetin between 1 and 10 μM,
with 34 8.2% inhibition at 1 μM, and amaximal effect of 87
3.7% (►Fig. 4A, B). Tamarixetin attenuated calcium elevation
lesspotently,with a signiﬁcant reductionbetween5 and10 μM
(►Fig. 4C, D). Quercetin also inhibited at all concentrations
tested, with a reducedmaximum effect of 61 6.8% compared
to isorhamnetin (►Fig. 4E, F).
Early Signaling Events Downstream of GPVI Are
Inhibited by Isorhamnetin and Tamarixetin
GPVI is a transmembrane collagen receptor associated with an
FcRγ-chain dimer. Upon ligand binding, strong platelet activa-
tion occurs, driven largely by protein kinase signaling. As the
methylated metabolites of quercetin inhibited platelet activa-
tionvia this pathway, their ability to inhibit phosphorylation of
signaling proteins downstream of GPVI, namely Syk and LAT,
was investigated. Upon stimulationwith CRP-XL (1 μg/mL), Syk
and LAT phosphorylation peaked at 40 seconds, decreasing
after this time up to 300 seconds (representative blots are
shown in ►Fig. 4G, H). Upon treatment with isorhamnetin
(7.5 μM, chosen as an intermediate concentration used in
aggregometry assays), peak Syk phosphorylation (the highest
level ofphosphorylationacross the time-course)wasdelayed to
90 seconds, and was inhibited by 51 16.2% compared to
control (►Fig. 4I). Tamarixetin delayed peak Syk phosphoryla-
tion to 90 seconds, with no signiﬁcant difference in peak levels
(►Fig. 4J). Quercetin treatment delayed peak Syk phosphory-
lation to 60 seconds, and, like isorhamnetin, inhibited it signif-
icantly (a 49 12% reduction, ►Fig. 4K).
Isorhamnetin potently inhibited the CRP-XL-stimulated
phosphorylation of LAT, with no real peak observed and a
signiﬁcant reduction compared to vehicle control between 25
and 40 seconds (►Fig. 4L). Tamarixetin again delayed peak
phosphorylation up to 90 seconds, with a 90% reduction com-
pared tovehicle control between30and40 seconds (►Fig. 4M).
Quercetin treatment resulted inadelay inpeakphosphorylation
up to 60 seconds; between 25 and 40 seconds, signiﬁcant
inhibition was observed, up to 90% (►Fig. 4N). There was,
however, no effect on peak phosphorylation levels by any
ﬂavonoid, possibly due to high inter-individual variance. These
data suggest that like quercetin, tamarixetin and isorhamnetin
both delay and impair phosphorylation of some of the immedi-
ate effectors of the GPVI pathway, likely leading to downstream
signaling alteration and the observed functional inhibition.
Isorhamnetin and Tamarixetin Inhibit Thrombus
Formation In Vitro
Due to the potent inhibitory effects of isorhamnetin and
tamarixetin on platelet function, it was hypothesized that
these metabolites of quercetin may demonstrate antithrom-
botic properties. The effects of these ﬂavonoids on thrombus
formation were therefore tested in vitro under physiological
arterial ﬂow conditions. Vehicle-treated blood perfused over
collagen formed thrombi normally, increasing in size as pla-
telets accumulated over the 10-minute assay period. Upon
ﬂavonoid treatment, thrombus formation (measured as an
increase in ﬂuorescence intensity) was inhibited from early
time points, reaching signiﬁcance from 140 seconds onward
upon isorhamnetin treatment, and from 210 seconds onward
upon tamarixetin and quercetin treatment (►Fig. 5A–C, rep-
resentative images shown inD). End pointﬂuorescence values
demonstrate a 41 5.9% inhibition of total thrombus forma-
tion upon isorhamnetin treatment, a 55 12% reductionwith
tamarixetin, and 39 8.9% inhibition with quercetin. This
trend toward an increased effect of tamarixetin is consistent
with clot retraction data in that, in the presence of plasma
proteins, a 4′-methyl group may confer higher inhibitory
potency over a 3′-methyl group or a B ring catechol moiety.
Isoquercetin Inhibits Thrombus Formation in a Murine
Model of Arterial Thrombosis
Havingdisplayedhigh inhibitorypotency invitro, thepotential
effect of quercetin on thrombosis invivowas investigated. This
was achieved using a laser injurymodel, inwhich thrombi are
induced in cremaster muscle arterioles and observed via
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Fig. 4 Isorhamnetin, tamarixetin, and quercetin inhibit calcium mobilization and signaling proximal to GPVI. Fura-2 loaded washed platelets
(4 108 cells/mL) were incubated with isorhamnetin (A, B), tamarixetin (C, D), quercetin (E, F), or vehicle control (DMSO, 0.2% v/v) for 5 minutes
at 37 °C prior to stimulation with CRP-XL (1 µg/mL). Fluorescence (excitation 340 and 380 nm, emission 510 nm) was recorded for 5 minutes
using a NOVOstar plate reader, and [Ca2þ]i was estimated using the equation described in the Methods (A, C, E). Peak [Ca
2þ]i was taken as the
maximum value reached in the sample over the 5-minute period, and was normalized to peak calcium levels in the absence of ﬂavonoid (vehicle)
(B, D, F). N¼ 4, data in (B), (D), and (F) represent mean SEM, analyzed by one-way ANOVA with posthoc Dunnett’s test. p< 0.05, p< 0.005,
p< 0.001, p< 0.0001 compared to vehicle control. Washed human platelets (4  108 cells/mL) were incubated with isorhamnetin (I, L),
tamarixetin (J, M), quercetin (K, N), or vehicle control (DMSO, 0.4% v/v) for 5 minutes at 37 °C prior to addition of CRP-XL (1 μg/mL). Aggregation
was allowed to occur for deﬁned time points, after which samples were immediately lysed in 6X reducing sample buffer. Proteins were separated
by SDS-PAGE and immunoblotted for phosphorylated Syk (Y525þ 526) and LAT (Y200). Levels of ﬂuorescence of individual bands were
normalized to loading controls (integrin β3), with representative blots shown in (G, H). N¼ 3, data represent mean  SEM. p< 0.05, p< 0.005,
p< 0.0001 compared to vehicle control at corresponding time points, analyzed by two-way ANOVA with posthoc Bonferroni correction. I,
isorhamnetin; LAT, linker for activation of T cells; Q, quercetin; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; Syk,
spleen tyrosine kinase; T, tamarixetin.
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intravital microscopy. Isoquercetin was used in these experi-
ments, as the route of administration was oral, and the
3-glucoside moiety results in higher bioavailability and plasma
quercetin concentrations compared to quercetin aglycone.28,29
Indeed, studies have demonstrated isorhamnetin and tamarix-
etin in plasma following isoquercetin administration, and after
supplementationwith other quercetin glucosides.12,30A48-hour
dosing regimenwasutilized,withmorningandafternoondosing,
tomimichumansupplemental consumption, and to investigate if
repeated supplementation resulted in antithrombotic effects.
Treatment with isoquercetin over 48 hours resulted in a
45 11.9% reduction in maximum thrombus size (►Fig. 5E).
Kinetically, upon injury, thrombi in vehicle-treated mice
increased in size, reaching a peak at approximately 160
seconds, after which the thrombus size gradually declined.
Upon isoquercetin administration, ﬂuorescence levels initially
rose similarly as platelets accumulated in the thrombus;
however, the growthwas not sustained, with thrombi becom-
ingunstable, platelets embolizing, and thrombiunable to grow
to the same degree (see ►Supplementary Videos 1 and 2,
and ►Fig. 5F). Representative images are shown in ►Fig. 5G.
Together, these data demonstrate the ability of an oral
isoquercetin dose to inhibit thrombosis in vivo, suggesting
that the antiplatelet effects of quercetin’s metabolites are
maintained in a whole, physiological system.
Video 1
Example of thrombus formation in vivo in vehicle-
treated mice. Online content including video sequences
available at: https://www.thieme-connect.com/
products/ejournals/html/10.1055/s-0039-1694028.
Video 2
Example of thrombus formation in vivo in isoquercetin-
treated mice. Online content including video sequences
available at: https://www.thieme-connect.com/
products/ejournals/html/10.1055/s-0039-1694028.
Quercetin and ItsMethylatedMetabolites Enhance the
Antiplatelet Effect of Aspirin
Aspirin use is associatedwith adverse bleeding events, and as
such the lowering of doses may be desirable; one way to
achieve this could be co-administration of ﬂavonoid supple-
ments.31,32 The effects of aspirin and ﬂavonoids on collagen
(5 μg/mL) stimulated platelet aggregation, both individually
and in combination, were therefore investigated.
Aspirin alone inhibited aggregation of washed platelets at
10 μM and above; combined ﬂavonoid and aspirin treatment
resulted in a signiﬁcantly higher level of inhibition compared
toaspirinaloneat2.5, 5, and10 μMisorhamnetin.A synergistic
(more-than-additive) enhancement of antiplatelet effect was
observed at 2.5 and 5 μM isorhamnetin; for example, treat-
ment with 5 μM isorhamnetin and 5 μM aspirin resulted in a
59 3.9% inhibition of aggregation, more than the sum of the
effects of these individual concentrations (14 1.4 and 4
2.3% inhibition, respectively; p< 0.05;►Fig. 6A). In►Fig. 6, an
“S” denotes a statistically signiﬁcantly greater effect of dual
treatment compared to the individual effects ofﬂavonoids and
aspirin added together (as opposed to simplyan additive effect
of including another inhibitor of platelet function). Similar
results were observed for both tamarixetin/quercetin and
aspirin dual treatment, with synergistic effects observed
upon treatment with 2.5 and 5 μM ﬂavonoid (►Fig. 6C, E).
The IC50 values for the inhibition of platelet aggregation by
aspirin upon ﬂavonoid co-administration highlight this inter-
active effect, with the IC50 value of 10.83 μM (0.45 μM) for
aspirin alone decreasing to 3.32 μM (1.08 μM), 2.99 μM
(0.44 μM), and 1.11 μM (0.4 μM) upon addition of 2.5, 5,
and 10 μM quercetin, respectively (►Fig. 6F). Indeed, upon
co-incubation of 10 μM isorhamnetin and tamarixetin, half-
maximal inhibition of aggregation was achieved at 0.8 μM
(0.36 μM) and 0.52 μM (0.1 μM) aspirin respectively, low-
ering the IC50 value of aspirin by over an order of magnitude
(►Fig. 6B, D). Together, these data demonstrate the ability of
isorhamnetin, tamarixetin, and quercetin to reduce the IC50
value of aspirin in the inhibition of aggregation at concen-
trations as low as 2.5 μM; plasma concentrations proven to be
physiologically relevant.23,33
The Antiplatelet Interaction between Flavonoids and
Aspirin is Maintained in a Whole Blood Assay of
Platelet Function
Havingestablishedsynergybetweenaspirinandthemethylated
metabolites of quercetin, we asked whether these interactions
weremaintained in awhole blood system, with the presence of
interfering factorssuchasplasmaproteins.Thiswas testedusing
a PFA-100 instrument, ﬁrst described by Kundu et al, which
simulates primary hemostasis by drawing anticoagulated blood
through an aperture cut into amembrane coatedwith collagen
plus ADP (CADP) and providing a measurement of CT of the
aperture upon its occlusion.34 Treatment of whole blood with
aspirin (25 μM), isorhamnetin, tamarixetin, or quercetin (10
μM) individually did not signiﬁcantly prolong the CT. However,
dual treatment with isorhamnetin and aspirin resulted in a
signiﬁcant prolongation of CT, from 115 seconds (13.8) in
vehicle-treatedwholebloodto250 50 secondsuponisorham-
netin/aspirin combined treatment. This effect was more than
additivewhen compared to individual treatmentwith isorham-
netin (CT: 113 9.8 s) and aspirin (CT: 115 15.9 s) alone. This
more-than-additive enhancement of the effect was also seen
upon dual treatment with tamarixetin/aspirin and quercetin/
aspirin, with average CTs of 253 47 and 255 30.3 seconds,
respectively (tamarixetin alone, CT: 121 15.9 s; quercetin
alone, CT 100 12.6;►Fig. 6G). These results provide evidence
for the maintenance of a more-than-additive interaction be-
tween quercetin and its methylated metabolites and aspirin in
the inhibition of platelet function inwhole blood, highlighting a
potential signiﬁcance of this interaction in vivo.
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Discussion
It has been demonstrated in many studies that diets high in
ﬂavonoids are associatedwith reduced CVD risk, and a better
understanding of the effects of dietary ﬂavonoids on platelet
function will help elucidate the mechanisms underlying
this.6Quercetin, one of thekey dietaryﬂavonoidsworldwide,
has been shown to dampen platelet function; however, on
ingestion it is metabolized extensively, and signiﬁcantly less
attention has been focused on these metabolites, the
Fig. 5 Isorhamnetin, tamarixetin, and quercetin display antithrombotic actions in vitro, and isoquercetin inhibits thrombosis in vivo. DiOC6-labelled whole
blood was incubated with isorhamnetin (A), tamarixetin (B), quercetin (C) (10 μM), or vehicle control (DMSO, 0.2% v/v) prior to perfusion through collagen-
coated Vena8 biochip channels at a shear rate of 20 dyn/cm2, with images captured every second for 600 seconds. Mean ﬂuorescence intensity was
normalized to the level in the absence of ﬂavonoid (vehicle) and was calculated using NIS Elements software (A–C), and representative images at the assay
endpoint are shown in (D). C57BL/6 mice were dosed twice per day (9 am and 5 pm) with isoquercetin (200mg/kg) or vehicle control (distilled water) by
gavage for 48 hours prior to the experiment, with one ﬁnal dose administered in the morning of the experiment. Mice were anaesthetized, platelets were
labeled with DyLight 649 anti-GPIbα antibody, and laser injury of a cremaster muscle arteriole wall was performed with a Micropoint ablation laser unit.
Thrombus formation was observed using an Olympus BX61W1 microscope, with images analyzed to calculate ﬂuorescence intensity of thrombi using
Slidebook software (version 6). Maximum ﬂuorescence of samples reached over the assay (E). Median-integrated ﬂuorescence values from all thrombi are
shown in (F). Representative images fromexperiments atdifferent timepoints are shown in (G); scalebars in bottom left of the images represent10 µm. For in
vitro data,N¼ 3, data representmean SEM. p< 0.05, p< 0.005, p< 0.001, p< 0.0001 compared to vehicle control, analyzedby two-wayANOVA
with posthoc Bonferroni correction. For in vivo data, N¼ 4, with multiple thrombi per mouse. p< 0.05 compared to vehicle control; data in (E) represent
mean SEM, analyzed by unpaired t-test.
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potential in vivo “effectors.”13,35 In this study, the antith-
rombotic effects and underlying mechanisms of two com-
mon physiological methylated metabolites of quercetin—
isorhamnetin and tamarixetin—were studied.
We report that the methylated metabolites of quercetin,
isorhamnetin and tamarixetin, potently inhibit platelet aggre-
gation stimulated by collagen, with effects observed as low as
1 μM; a total plasma quercetin concentration achievable
through both diet and supplemental means.23,33 As the pri-
mary, initial stimulus upon vessel injury, a strong inhibition of
collagen-stimulated platelet aggregation by the methylated
metabolites ofquercetin suggests early inhibitoryeffects, upon
initial hemostatic challenge.21 Platelet aggregation stimulated
viaGPCRpathways, crucial for thepositive feedback associated
with platelet activation, was also affected. The ability of these
ﬂavonoids to inhibit this multitude of activatory pathways is
likely through inhibition of kinases which are involved in both
the initiation and propagation of platelet responses. Indeed, it
has been shown that quercetin is able to inhibit the activity of
many tyrosine and lipid kinases involved in platelet activation
including Lyn, Fyn, Src, AKT, Syk, and phosphoinositide
3-kinase (PI3K).13,36 The inhibition of activation through
multiple GPCR pathways likely, at least in part, underlies the
potent inhibition seenwith theseﬂavonoids. Secondary plate-
let activation through GPCR-activating ligands is key for the
positive feedback mechanisms that are necessary for a rapid
and robust platelet response.2 Dampened initial responses to
collagen and subsequent inhibited GPCR signaling may be
responsible for the high level of inhibition seen following
exposure to quercetin metabolites, with platelets unable to
activate fully due to inhibition of multiple key pathways.
Consistent with an effect on platelet aggregation, isorham-
netin and tamarixetin potently inhibited granule secretion,
with an effect on α-granule secretion at submicromolar con-
centrations. The mechanisms underlying the inhibition of
granule secretion were not investigated; however, ﬂavonoids
have been shown to interfere with SNARE (soluble NSF attach-
ment protein receptor) complex formation in mast cells, and
quercetin has also demonstrated actin-binding properties,
inhibiting its polymerization.37,38 In addition to this, inhibition
of upstream activatory events (Ca2þ mobilization, receptor-
proximal signaling events, etc.) may suppress downstream
granule secretion.
A signiﬁcant inhibition of integrin αIIbβ3 functionwas also
demonstrated. The initial conformational change opening the
integrin into a high-afﬁnity state that binds ﬁbrinogen was
strongly attenuated by quercetin, offering amechanistic expla-
nation for the observed reduction in aggregation. An increased
potency of the aglycone over the methylated metabolites here
may imply the presence of a potent uninvestigatedmetabolite.
Indeed, quercetin is metabolized extensively upon consump-
tion; Hong and Mitchell identiﬁed 17 metabolites in human
urine following consumption of cooked onions, and Lee et al
identiﬁed 15metabolites in human plasma following enriched
Fig. 6 Isorhamnetin, tamarixetin, and quercetin synergize with aspirin to enhance antiplatelet effects. Washed platelets (2 108 cells/mL) were
incubated in a 96-well plate with aspirin isorhamnetin (A, B), tamarixetin (C, D), quercetin (E, F) (5 µM ﬂavonoid shown as example), or vehicle
control (0.25% ethanol þ 0.5% DMSO, v/v), and aggregation stimulated by collagen (5 µg/mL). Data represent percentage aggregation
normalized to levels of aggregation in the absence of ﬂavonoid (vehicle) (A, C, E). (B, D, F) IC50 values for aspirin upon addition of ﬂavonoid. N ¼
3, data represent mean SEM. p< 0.05, p< 0.005, p< 0.001, p< 0.0001. Blue stars indicate a signiﬁcant effect of aspirin compared to
vehicle control, analyzed by one-way ANOVA. Black stars indicate a signiﬁcant effect of ﬂavonoid plus aspirin compared to aspirin alone, analyzed
by two-way ANOVA. “S” indicates an enhanced effect of dual treatment compared to the combined effects of individual ﬂavonoid and aspirin
concentrations (p< 0.05), analyzed by paired t-test. Whole blood was incubated with quercetin  aspirin, tamarixetin aspirin, isorhamnetin 
aspirin, aspirin alone, or vehicle control (0.1% DMSOþ 0.1% ethanol) for 30 minutes at 30 °C. Whole blood was loaded into the reservoir of CADP
cartridges and samples were run through the PFA-100, with closure time (s) shown in (G). N ¼ 3, data represent mean SEM. Stars represent a
signiﬁcant prolongation of closure time compared to vehicle control. p< 0.05, analyzed by one-way ANOVA. “S” represents a synergistic effect
as described above. ASA, acetylsalicylic acid (aspirin); CADP, collagen plus adenosine diphosphate; I, isorhamnetin; Q, quercetin; T, tamarixetin.
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apple sauce consumption.39,40 It may also be that, in vivo, it is
the combinations of metabolites that act together to potently
inhibit platelet function. In addition, whilst the methylated
metabolites may demonstrate increased effects at lower ﬂavo-
noid concentrations, quercetin may have a larger maximal
effect on integrin inside-out signaling; the reason for this is
unclear but may be due to structural differences in the ﬂavo-
noids. The adhesion and spreading of platelets on a ﬁbrinogen-
coated surface was also reduced upon ﬂavonoid treatment,
with an effect on integrin outside-in signaling conﬁrmed with
the observation of reduced clot retraction upon ﬂavonoid
treatment. Thus, quercetin and its methylated metabolites
dampen integrin αIIbβ3 function downstream of GPVI and
PAR1/4 activation. Such inhibition of clot retraction may be
mediated via speciﬁc antiplatelet effects, such as disruption of
actin cytoskeletal arrangement and recruitment of cytoskele-
tal-associated proteins such as myosin heavy chain to β3.41 In
addition tothis, Src familykinases (SFKs), speciﬁcallyc-Src,have
been shown to be crucial for integrin outside-in signaling, and
quercetin potently inhibits SFKs including Fyn and Lyn.35,42 An
inhibition of platelet activation induced by thrombin here
agrees with the GPCR-stimulated aggregometry presented in
this study, and offers further evidence for quercetin and its
metabolites as inhibitors of the thrombin-stimulated platelet
activation pathway, even in the presence of plasma proteins.
Quercetin has also exhibited anticoagulant activities in numer-
ous studies, including inhibitory effects on the enzymatic
activity of thrombin and Factor Xa.43,44 Thus, the potential
anticoagulant effects of quercetin’s methylated metabolites
must also be considered.
Many ﬂavonoids have been shown to inhibit intracellular
enzymes key in signal transduction. For example, in platelets
alone, it has been demonstrated that citrus ﬂavonoids such as
nobiletin inhibit PI3K-mediated signaling cascades, and genis-
tein, luteolin, apigenin, and quercetin inhibit total tyrosine
phosphorylation and extracellular signal-regulated kinase
(ERK)1/2 activation upon U46619 stimulation.18,45 As such,
and due to the observed inhibition of early activation events
suchasgranule secretion in this study, itwashypothesized that
signaling events proximal to the GPVI receptor may be attenu-
ated by the methylated metabolites of quercetin. Indeed, the
phosphorylation of Syk and LAT, very early signaling events in
platelets upon GPVI activation, were inhibited potently by
isorhamnetin, tamarixetin, and quercetin. This likely explains
previous observations that collagen-stimulated phosphoryla-
tion of phospholipase Cγ2 is inhibited ex vivo after quercetin
ingestion, as well as by quercetin and tamarixetin in vitro.12,46
Consistent with this, CRP-XL-stimulated mobilization of calci-
um was reduced upon ﬂavonoid treatment. This alteration of
early platelet signaling events likely explains the potent func-
tional inhibition observed, with the mobilization of calcium
driving key processes such as integrin activation, TXA2produc-
tion, and granule secretion.47 Indeed, inhibition early in the
GPVI signaling pathway at the level of Syk and LAT (and
subsequent calcium mobilization) is also likely to explain the
inhibition of CRP-XL/collagen-stimulated granule secretion,
ﬁbrinogen binding, and platelet aggregation observed in this
study, with these signaling molecules crucial to downstream
platelet activation. The multitude of pathways and platelet
functions inhibited by quercetin and its methylated metabo-
lites in this study are displayed in►Fig. 7. In addition to this, a
recent study by Doucet et al identiﬁed a peracetylated querce-
tin as a selective inhibitor of the 12-lipoxygenase pathway, a
pathway essential for platelet activation through the low-
afﬁnity receptor for IgG, FcγRIIa; it may therefore be that the
methylated metabolites of quercetin dampen platelet activa-
tion through this mechanism.48,49
This studyalso demonstrates an antithrombotic effect of the
methylated metabolites of quercetin, measured in vitro as an
inhibition of thrombus formation under arterial ﬂow condi-
tions. A concentration of 10μM was used in this assay, corre-
sponding to a physiologically achievable total plasmaquercetin
(plus metabolite) concentration upon supplementation.12,23 A
trend toward increased potency of tamarixetin over quercetin
and isorhamnetin was observed, similar to effects in clot
retraction. These data therefore demonstrate the increased
antiplatelet effect of a quercetin metabolite compared to the
parent aglycone, offering insight into how quercetin consump-
tion could lead to antiplatelet efﬁcacy in vivo. The cause of
increased potency is not established here, but there are several
potential explanations for this. It has been demonstrated that
tamarixetin binds collagen and ﬁbrinogenwith a much higher
afﬁnity thanquercetin; this could interferewithplatelet–ligand
binding in this assay, which relies on a collagen-coated surface
for platelet activaton.46 A study by Dufour and Dangles
observed a two to three times reduction in binding constants
to bovine serum albumin uponmethylation of quercetin at the
4′-hydroxyl residue; reducedbinding to albuminmay therefore
result in greater levels of available metabolite and therefore an
apparent increase in efﬁcacy.50 It is hypothesized that the
enhanced potency of tamarixetin is not, therefore, due to
increased antiplatelet activity per se, but rather altered bio-
availability/platelet–ligand binding.
An antithrombotic effect was demonstrated in vivo upon
oral supplementation in mice with 200mg/kg isoquercetin
over a 48-hour period. Thrombi were unstable and prone to
embolization upon isoquercetin treatment; this may be due to
impaired integrin αIIbβ3 outside-in signaling, which has a
proven role in thrombus stabilization and is shown in the
present study to be attenuated by quercetin and itsmethylated
metabolites.51 A recent study by Feng et al reported a similar
phenotype in a knock-in mouse with impaired β3 phosphory-
lation which displayed delayed vessel occlusion and unstable
thrombi upon injury.52 Isoquercetin itself is unlikely to be
identiﬁed in plasma after oral supplementation due to glyco-
side hydrolysis by enzymes such as enterocyte lactin-phlorizin
hydrolase (LPH) and β-glucosidases.53 Indeed, upon oral iso-
quercetin administration, Paulke et al identiﬁed isorhamnetin/
tamarixetin in rat plasma.29 The identiﬁcation of the active
metabolite(s) in the in vivo assay presented in this study, and
their pharmacokinetic parameters, is therefore a primary goal
of further research. A previous study from Hubbard et al also
identiﬁed isorhamnetin and tamarixetin in human plasma
upon ingestionofquercetin-4′-O-β-D-glucoside, aglucosidated
form of quercetin similar to isoquercetin.12 Isorhamnetin and
tamarixetin displayed similar pharmacokinetic properties to
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quercetin, accumulating with a tmax between 30 and 45
minutes.12 Thus, with repeated dosing through diet or supple-
mentation, itmaybepossible that thesemetabolites (and other
as yet unidentiﬁed metabolites) may accumulate in plasma or
within platelets and exert their antiplatelet activities as
established in this study. Indeed, a study evaluatingmetabolite
identiﬁcation and pharmacokinetics post-isoquercetin supple-
mentation in humans is another goal of further research.
Nevertheless, these data demonstrate both the oral
bioavailability of isoquercetin and a protective effect against
thrombosis.
Aspirin is one of the most widely used antiplatelet agents
worldwide.54 Its use is associated with adverse events such as
gastric bleeding, and whilst studies have shown that decreas-
ing aspirin doses reduces adverse event numbers without a
reduction in antiplatelet efﬁcacy, even low-dose aspirin treat-
ment is associated with an increased bleeding risk.31,32 As
such, the pharmacological implications of the effects of the
methylated metabolites of quercetin with respect to the
antiplatelet effects of aspirin are worthy of consideration. A
preliminary investigation in this study demonstrated that
isorhamnetin, tamarixetin, and quercetin all increased the
antiaggregatory effects of aspirin in a synergistic, i.e., more-
than-additivemanner, lowering IC50 values byover an order of
magnitude at higher concentrations. In addition to this,
isorhamnetin, tamarixetin, and quercetin enhanced the effect
of aspirin in awholeblood assay of platelet function (PFA-100)
more-than-additively. The mechanism underlying this inter-
action is not established here but could be for several reasons.
Several studies have demonstrated the ability of quercetin to
directly inhibit COX-1 activity; indeed, Al-Fayez et al estab-
lished an IC50 of5 μM on puriﬁed COX-1.55,56 In vivo metab-
olites of quercetin may therefore be able to inhibit COX-1 at
physiologically relevant levels. Thisholdsclear implications for
thromboxane synthesis. Indeed, Guerrero et al showed that
quercetin can inhibit the production of thromboxane B2
downstream of collagen and arachidonic acid stimulation of
platelets.57 Co-administration with ﬂavonoids may therefore
allow further lowering of aspirin doses to be achieved. It must
also be considered that such interactions between the effects
of dietary ﬂavonoids and aspirinmay act as interfering factors
in the use of antiplatelet agents, potentially explaining vari-
ability in responseto suchagents. Further research isneeded to
elucidate the potentially helpful (enhanced antithrombotic
effect) or harmful (compromised hemostasis) effects of ﬂavo-
noid–antiplatelet medication interactions in vivo.
Our study has demonstrated that isorhamnetin and tam-
arixetin inhibit platelet function and thrombus formation
througheffectsonearlyactivatoryprocesses includingcalcium
mobilization, granule secretion, and integrin activation. These
metabolites, as well as quercetin aglycone, synergize with
aspirin to enhance antiplatelet efﬁcacy. Combined with the
in vivo antithrombotic effect of isoquercetin demonstrated
here, this may offer insight into new CVD treatment avenues,
and offer evidence into the link between ﬂavonoid intake and
reduced CVD risk.
Fig. 7 A model demonstrating the multiple platelet activation pathways inhibited by the methylated metabolites of quercetin. Isorhamnetin,
tamarixetin, and quercetin inhibit multiple aspects of the GPVI activation pathway, including Syk and LAT phosphorylation, alpha and dense
granule secretion, calcium mobilization, integrin αIIbβ3 inside-out signaling and, ultimately, aggregation (indicated by the red text). In addition,
this study demonstrates an inhibition of platelet aggregation downstream of ADP, thrombin, and U46619 stimulation. This multitude of
inhibitory effects culminates in the potent inhibition observed upon treatment with isorhamnetin, tamarixetin, or quercetin, and results in
attenuated thrombus formation. ADP, adenosine phosphate; GPCR, G-protein coupled receptor; GPVI, glycoprotein VI; I, isorhamnetin; IP3,
inositol 1,4,5-trisphosphate; LAT, linker for activation of T cells; PLCγ2, phospholipase Cγ2; PIP2, phosphatidylinositol 4,5-bisphosphate; Q,
quercetin; Syk, spleen tyrosine kinase; T, tamarixetin; TXA2, thromboxane A2.
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